Orion Oyj B (0M2O)
London Exchange · UK · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 91.68 |
|---|---|
| 52-week range | 56.55 – 91.68 |
| Return, 1 month / 3 months | +9.4% / +19.0% |
| Return, 1 year / 3 years | +36.7% / +164.7% |
| Trend | Uptrend |
| RSI (14) | 78 |
| Volatility (1 year) | 32.9% |
| Worst drawdown (1 year) | -16.9% |
| Average daily value traded | 1.98M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Orion Oyj is a Finnish pharmaceutical company based in Espoo that develops, manufactures and markets prescription medicines, generic drugs and over-the-counter products. Its prescription portfolio focuses on treatments for central nervous system disorders, cancer and respiratory conditions, while its consumer health range includes pain relievers and other self-care medicines. The company also produces veterinary medicines and active pharmaceutical ingredients, serving healthcare professionals, pharmacies and wholesalers in Finland and through partners in other markets.
On this site Orion Oyj B appears as a stock on the London Exchange (UK), code 0M2O, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Orion Oyj B (0M2O) trades on the London Exchange in UK. It last closed at EUR 91.68 on 22 October 2026.
Its price-based Market X-Ray is 77 out of 100 (a strong price profile), ranking 155 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 36.7% and over the last three months it rose 19.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 90 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 24.6% | ||
| From 52-week high | 0.0% | ||
| Momentum | 82 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 19.0% | ||
| 6-month return | 25.0% | ||
| 12-month return, skipping the last month | 25.0% | ||
| Stability (higher is calmer) | 68 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 32.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -16.9% | ||
| Liquidity | 60 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.98M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +5.7% |
|---|---|
| 1 month | +9.4% |
| 3 months | +19.0% |
| 6 months | +25.0% |
| 1 year | +36.7% |
| 3 years | +164.7% |
| 5 years | +187.5% |
Signals
| 50-day / 200-day average | 81.65 / 73.58 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.59 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Oct 2025 | EUR 0.8200 |
| 4 Apr 2025 | EUR 0.8200 |
| 15 Oct 2024 | EUR 0.8100 |
| 21 Mar 2024 | EUR 0.8100 |
| 23 Mar 2023 | EUR 1.6000 |
| 24 Mar 2022 | EUR 1.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.